CDTX Stock Risk & Deep Value Analysis
Cidara Therapeutics Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About CDTX Stock
We analyzed Cidara Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran CDTX through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is CDTX Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
Medium
Execution Risk
Medium
Regulatory Risk
High
What Are the Red Flags for CDTX?
- âš
Lower-than-expected REZZAYO® commercial sales ramp or increased competition.
- âš
Negative or inconclusive clinical trial results for Cloudbreak platform candidates.
- âš
Termination or renegotiation of key partnerships (e.g., Janssen).
- âš
Significant dilution through equity raises to fund R&D.
Unlock CDTX Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does Cidara Therapeutics Inc (CDTX) Do?
Market Cap
$3.43B
Sector
Healthcare
Industry
Biotechnology
Employees
38
Cidara Therapeutics, Inc. operates as a biotechnology company that focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. Cidara Therapeutics, Inc. was incorporated in 2012 and is based in San Diego, California.
Visit Cidara Therapeutics Inc WebsiteIs CDTX Stock Undervalued?
Unlock the full AI analysis for CDTX
Get the complete DVR score, risk analysis, and more
Does CDTX Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
The moat is primarily derived from Cidara's intellectual property protecting Rezafungin and the Cloudbreak platform. As Cloudbreak advances clinically and secures additional partnerships, its unique approach to antiviral discovery strengthens the moat by making it harder for competitors to replicate its broad-spectrum potential without similar foundational technology or partnerships.
Moat Erosion Risks
- •Expiration of key patents or successful challenges by generic competitors.
- •Clinical failures of Cloudbreak candidates, diminishing platform value.
- •Competitors developing superior or faster-to-market broad-spectrum antiviral technologies.
CDTX Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive CDTX Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated early March 2026): Focus on Rezafungin sales growth and cash burn.
- •Update on REZZAYO® commercial expansion or new indication filings (Q1-Q2 2026).
- •IND filing or preclinical data presentation for a new Cloudbreak program (H1 2026).
Medium-Term (6-18 months)
- •Phase 1 clinical trial initiation/data for a lead Cloudbreak antiviral candidate (H2 2026 - H1 2027).
- •New strategic partnership announcement for Cloudbreak platform or specific antiviral target (2027).
- •Further expansion of REZZAYO® into international markets or additional indications (2027).
Long-Term (18+ months)
- •Cloudbreak platform's potential to deliver a universal flu vaccine or broad-spectrum antivirals, disrupting infectious disease treatment paradigms (2028+).
- •Establishment as a leading player in novel antifungal and antiviral therapies.
- •Acquisition by a larger pharmaceutical company seeking infectious disease platform technology.
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for CDTX?
- âś“
Acceleration in REZZAYO® net product sales and positive updates on market penetration.
- âś“
Announcements of new Cloudbreak development candidates entering clinical trials or securing new collaboration agreements.
- âś“
Positive preclinical or early clinical data readout for any Cloudbreak antiviral program.
Bull Case Analysis
See what could go right with Premium
đź“Š Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for CDTX (Cidara Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
